From the CABANA trial: Patients with #HFpEF benefited even more from #Afib ablation regarding:
🔸Death/CV 🏥
🔸AF recurrence
Despite the greater benefit for HFpEF pts, their risk of recurrence remained ⬆️ than in those w/out HFpEF
📎: jacc.org/doi/10.1016/j.jchf.…#JACCHF
Great start with our fearless leader @BurkhoffMd kicking off exciting #THT2024 with 3 days of packed agenda and exciting discussions in #heartfailure innovations.
The new #JACCHF issue is now out!
Hemodynamic gain index and peak rate pressure product can identify patients w/ #HFrEF at risk of poor clinical outcomes. This allows prognostication of #HeartFailure even when CPET is not available. bit.ly/49p3hjk#CHF@WilsonTangMD
The MF is thrilled to announce one of the 2023 Fellowship Grant recipients, Dr. Simon Vanhentenrijk, MD, Pharm D, of the Cleveland Clinic!
Read about his work below.
myocarditisfoundation.org/th…
Q: Is intravenous iron beneficial for patients with #heartfailure and iron deficiency?
A: In patients with HF and iron deficiency, treatment with IV iron can reduce CV deaths and HF hospitalizations.
bit.ly/4aL4MKs#JACCHF
Prognostic Value of Natriuretic Peptide Levels for Adverse Renal Outcomes in Patients With Moderate to Severe Acute Kidney Injury With or Without Heart Failure. #AHAJournals@WilsonTangMDahajrnls.org/40J9bcl
This phase 3 trial of patisiran, a small interfering RNA that targets hepatic production of the transthyretin protein, showed efficacy in treating transthyretin-mediated (ATTR) cardiac amyloidosis. Read the full APOLLO-B trial results: nej.md/4081o7o